HomeCompareTCBPW vs XYLD

TCBPW vs XYLD: Dividend Comparison 2026

TCBPW yields 33333.33% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCBPW wins by $8.428195308647591e+21M in total portfolio value
10 years
TCBPW
TCBPW
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full TCBPW calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — TCBPW vs XYLD

📍 TCBPW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCBPWXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCBPW + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCBPW pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCBPW
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, TCBPW beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCBPW + XYLD for your $10,000?

TCBPW: 50%XYLD: 50%
100% XYLD50/50100% TCBPW
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCBPW buys
0
XYLD buys
0
No recent congressional trades found for TCBPW or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCBPWXYLD
Forward yield33333.33%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.428195308647591e+21M$25.3K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$3,219.02
Total dividends collected$8.424943808765552e+21M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TCBPW vs XYLD ($10,000, DRIP)

YearTCBPW PortfolioTCBPW Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$3,344,033$3,333,333.33$10,818$1,098.39+$3.33MTCBPW
2$1,045,333,048$1,041,754,932.50$11,738$1,222.51+$1045.32MTCBPW
3$305,463,295,767$304,344,789,404.97$12,774$1,364.64+$305463.28MTCBPW
4$83,443,192,327,233$83,116,346,600,762.75$13,944$1,527.86+$83443192.31MTCBPW
5$21,308,754,850,592,396$21,219,470,634,802,260.00$15,270$1,715.87+$21308754850.58MTCBPW
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$16,775$1,933.09+$5087082937849.44MTCBPW
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$18,490$2,184.87+$1135355897925379.50MTCBPW
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$20,450$2,477.63+$236895694937506176.00MTCBPW
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$22,697$2,819.19+$46211962155546607616.00MTCBPW
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$25,280$3,219.02+$8.428195308647591e+21MTCBPW

TCBPW vs XYLD: Complete Analysis 2026

TCBPWStock

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Full TCBPW Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this TCBPW vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCBPW vs SCHDTCBPW vs JEPITCBPW vs OTCBPW vs KOTCBPW vs MAINTCBPW vs QYLDTCBPW vs JEPQTCBPW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.